
SPRB Stock Forecast & Price Target
SPRB Analyst Ratings
Bulls say
Spruce Biosciences Inc is well-positioned to capitalize on the growing market for rare endocrine disorders, particularly with its lead product candidate TA-ERT, which has demonstrated significant efficacy in improving cognitive and communicative functions in patients with MPS IIIA. The company benefits from substantial financial backing, having secured up to $50 million from Avenue Capital, contingent on achieving key regulatory milestones, which underscores investor confidence in its development pipeline. Additionally, the successful commercialization of enzyme replacement therapies (ERTs) in similar markets suggests a strong revenue potential for TA-ERT, bolstered by its differentiated mechanism of action and favorable safety profile compared to existing therapies.
Bears say
Spruce Biosciences Inc faces significant financial challenges as it continues to incur net losses, a situation expected to persist at least until the commercialization of its product candidate, TA-ERT. The company has not yet commercialized any products and will require substantial investment to build the infrastructure necessary for a successful launch, which introduces risks of medium-term dilution. Additionally, recent FDA feedback indicates hurdles in achieving regulatory approval and the potential for underwhelming commercial success due to competitive market factors and slow uptake, further contributing to a negative financial outlook.
This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SPRB Analyst Forecast & Price Prediction
Start investing in SPRB
Order type
Buy in
Order amount
Est. shares
0 shares